Amplifications were seen in 30% of Luminal B (HER2+), 18% of HER2 type, 12% of Luminal B (HER2−), and 3% of Luminal A. Of the MRPS23 amplified tumours, 19 (42%) were HER2+ , compared to 58 (11%) of non-amplified tumours. Here, MRPS23 is linked to neoplasm.